About the Journal

Precision Cancer Medicine

Precision Cancer Medicine (PCM, Precis Cancer Med, ISSN: 2617-2216) is an open access, peer-reviewed online journal. It aims at better understanding and management of cancers by exploring in pathological mechanism and genetic changes of cancer, tailoring therapeutic decisions and developing targeted therapies or individually customized strategies. The journal focuses on advanced basic researches, translational researches and up-to-date clinical practice in the field of precision cancer medicine. It is to improve the health care from all aspects of prevention, diagnosis, treatment and recovery management of cancer care for the patients, with the engagement of multidisciplinary teams that involve scientists, clinicians, pathologists, radiologists, etc.

To provide an international platform for health care professionals to discuss on important issues, exchange ideas and share research results and new discoveries in terms of precision cancer researches, PCM welcomes submissions of original articles, review articles, editorials, case reports, clinical guidelines, commentaries and perspectives.

AME Publishing Company:
Address: Rm C, 16/F, Kings Wing Plaza 1, No. 3 On Kwan Street, Shatin, NT, Hong Kong
Phone: +86 20 66355775
Email: pcm@amegroups.com


PCM is the official journal of Fudan University Shanghai Cancer Center.

Fudan University Shanghai Cancer Center (FUSCC, http://www.shca.org.cn/english), is engaged in clinical practice, medical education, oncological research and cancer prevention in China. Historically, it can be traced back to Sino-Belgian Radium Institute established on March 1, 1931, the earliest specialized hospital of oncology in China.

FUSCC topped the counterparts across the China in terms of medical operation efficiency. The year of 2017 witnessed 1,339,000 outpatient and emergency visits, including 160,000+ first visits; 37,284 surgeries and 76,381 hospitalizations. As to scientific research, they published 338 SCI papers in journals such as JCO, Nature, JNCI, etc.

FUSCC, while deeply committing to the basic mission to care for the patient, is dedicated to building national and international collaborative partnerships and cherishing its influential image.

Internationally, FUSCC signed the sister-institution agreement, respectively, with MD Anderson Cancer Center at Texas in USA; National University Cancer Institute Singapore; Institut Gustave Roussy in France; Cancer Research Institute of Kanazawa University, Japan; European Institute of Oncology, Italy; DUKE Cancer Institute, USA; Peter MacCallum Cancer Centre, Australia; and The Princess Margaret Cancer Centre, Canada for the purpose of promoting bilateral collaborations and exchanges in therapy, research, training and referral. So far, FUSCC has established eight sister-institution/hospital partnerships, advancing the construction of its own disciplines and improving its academic prestige in the world.